Hemostasis and Tissue Sealing Agents Market is Increasing at a Sturdy CAGR of 8.6% During Forecast to 2023
Market Analysis:
Various factors are adding to the global hemostasis
and tissue sealing agents market share. These factors, as per the new MRFR
report, include increasing FDA approvals for different hemostatic methods,
rising surgery volumes, increasing geriatric population, a constant boost in
medical conditions that need surgeries worldwide, and rising prevalence of
pulmonary, cardiovascular, vascular, and gastrointestinal surgeries. Additional
factors adding market growth include increasing use of hemostat products by
physicians and surgeons, the rising number of inpatient surgeries, and increasing
cases of chronic conditions.
The Hemostasis & Tissue Sealing
Agents Market Share is predicted to grow
at an 8.6% CAGR between 2018- 2023, reveals the new Market Research Future
(MRFR) report. Hemostasis and tissue sealing agents, simply put, are materials
used to restrict hemorrhage or bleeding during surgical procedures or from
injuries.
On the contrary, high surgical procedure costs in
developing countries, and lack of reimbursement policies are factors that may
limit the hemostasis and tissue sealing agents market growth over the forecast
period.
Key Players:
Advanced Medical Solutions Group Plc, MIL
Laboratories Pvt. Ltd,. B. Braun Melsungen AG, Medtronic plc, Pfizer, Inc,
Cohera Medical, Inc., Dickinson & Company, Becton, Integra Lifesciences
Corporation, Ethicon LLC, Baxter International, Inc, Cryolife, Inc., and
Johnson & Johnson
Market Segmentation:
The MRFR report offers an inclusive segmental
analysis of the global hemostasis and tissue sealing agents market based on end
user and product.
By product, the hemostasis and tissue sealing agents
market is segmented into adhesive & tissue sealant, and topical hemostats.
The topical hemostats segment is again segmented into flowable, mechanical
(polysaccharide based hemostats, gelatin based hemostats, cellulose based
hemostats, and collagen based hemostats. Adhesive & tissue sealant is again
segmented into adhesion barrier, natural, and synthetic. Of these, the topical
hemostats segment is predicted to lead the market over the forecast period for
these agents’ quick absorbability, non-antigenicity, minimal tissue reactivity,
and cost-efficiency. Similarly, adhesive & sealants too, play a pivotal
role in limiting blood loss during different surgical processes and needs
minimal invasion.
By end user, the hemostasis and tissue sealing
agents market is segmented into ambulatory centers, hospitals, and others. Of
these, hospitals will spearhead the market over the forecast period for the
rising number of patients visiting emergency departments coupled with the
increasing number of surgeries conducted at multi-specialty hospitals.
Regional Analysis:
Based on the region, the global hemostasis and
tissue sealing agents market report covers the recent trends and growth
opportunities across Europe, the Americas, the Asia Pacific (APAC), Latin
America, and the Middle East and Africa (MEA). Of these, the Americas will
dominate the market over the forecast period for the increasing number of
surgical procedures, the presence of top manufacturers in the region, and high
clinical research and development budgets by private & public organizations
and also the government.
The hemostasis & tissue sealing agents market in
Europe is predicted to hold the second-largest share over the forecast period
for swift approval to technologically advanced and new products in the
healthcare system and rising incidence of surgical procedures.
The hemostasis & tissue sealing agents market in
the APAC region is likely to develop at the fastest pace during the forecast
period for increasing healthcare expenditure, especially in developing
countries and increased medical tourism for surgical procedures.
The hemostasis & tissue sealing agents market in
the MEA is predicted to have the smallest share over the forecast period. The
major share is held by the Middle East region for the increasing initiatives by
the government for the healthcare sector.
Comments
Post a Comment